Clonidine/oxybutynin - Orient Pharma
Alternative Names: DL 06001; OP-014; SMT D001Latest Information Update: 05 Apr 2021
Price :
$50 *
At a glance
- Originator DanioLabs
- Developer Orient Pharma
- Class Alkynes; Analgesics; Antiglaucomas; Antimigraines; Antispasmodics; Behavioural disorder therapies; Carbocyclic acids; Centrally-acting antihypertensives; Chlorobenzenes; Cyclohexanes; Diethylamines; Esters; Imidazolines; Mandelic acids; Small molecules
- Mechanism of Action Alpha 2 adrenergic receptor agonists; Cholinergic receptor antagonists; Imidazoline receptor agonists; Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Sialorrhoea
Most Recent Events
- 05 Apr 2021 Discontinued - Preregistration for Sialorrhoea in South Korea, New Zealand, India, Malaysia, Hong Kong, Japan, Philippines, China, Canada, European Union, USA (PO) (NDR Batch 18)
- 25 Jan 2019 Clonidine/oxybutynin is not yet available for Sialorrhoea in Australia and Singapore (PO)
- 25 Jan 2019 No recent reports of development identified after preregistration for Sialorrhoea in USA, European Union, Canada, China, China, Japan, Philippines, Hong Kong, Malaysia, India, New Zealand, South Korea (PO)